Annexon (ANNX) Revenue & Revenue Breakdown
Annexon Revenue Highlights
00
Annexon Revenue by Period
Annexon Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Annexon Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $4.87M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
Annexon Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
RCUS | Arcus Biosciences | $117.00M | $48.00M |
WVE | Wave Life Sciences | $113.31M | $19.69M |
VECT | VectivBio | $27.34M | $676.00K |
RLAY | Relay Therapeutics | $25.55M | - |
KRTX | Karuna Therapeutics | $654.00K | - |
CGEM | Cullinan Oncology | - | - |
GPCR | Structure Therapeutics | - | - |
XFOR | X4 Pharmaceuticals | - | $560.00K |
AVRO | AVROBIO | - | - |
CNSP | CNS Pharmaceuticals | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
ZURA | Zura Bio | - | - |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
INAB | IN8bio | - | - |
ANNX | Annexon | - | - |
IMMX | Immix Biopharma | - | - |
HEPA | Hepion Pharmaceuticals | - | - |